Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai, 200127, China.
SmartNuclide Biopharma Co. Ltd, 218 Xinghu St., BioBAY A4-202, Suzhou Industrial Park, Suzhou, China.
J Nanobiotechnology. 2021 Feb 9;19(1):42. doi: 10.1186/s12951-021-00785-9.
Although immunotherapy has revolutionized treatment strategies for some types of cancers, most patients failed to respond or obtain long-term benefit. Tumor-infiltrating CD8 T lymphocytes are closely related to the treatment outcome and prognosis of patients. Therefore, noninvasive elucidation of both systemic and tumor-infiltrating CD8 T lymphocytes is of extraordinary significance for patients during cancer immunotherapy. Herein, a panel of Ga-labeled Nanobodies were designed and investigated to track human CD8 T cells in vivo through immuno-positron emission tomography (immunoPET).
Among the screened Nanobodies, SNA006a showed the highest binding affinity and specificity to both human CD8 protein and CD8 cells in vitro, with the equilibrium dissociation constant (K) of 6.4 × 10 M and 4.6 × 10 M, respectively. Ga-NOTA-SNA006 was obtained with high radiochemical yield and purity, and stayed stable for at least 1 h both in vitro and in vivo. Biodistribution and Micro-PET/CT imaging studies revealed that all tracers specifically concentrated in the CD8 tumors with low accumulation in CD8 tumors and normal organs except the kidneys, where the tracer was excreted and reabsorbed. Notably, the high uptake of Ga-NOTA-SNA006a in CD8 tumors was rapid and persistent, which reached 24.41 ± 1.00% ID/g at 1.5 h after intravenous injection, resulting in excellent target-to-background ratios (TBRs). More specifically, the tumor-to-muscle, tumor-to-liver, and CD8 to CD8 tumor was 28.10 ± 3.68, 5.26 ± 0.86, and 19.58 ± 2.70 at 1.5 h, respectively. Furthermore, in the humanized PBMC-NSG and HSC-NPG mouse models, Ga-NOTA-SNA006a accumulated in both CD8 tumors and specific tissues such as liver, spleen and lung where human CD8 antigen was overexpressed or CD8 T cells located during immunoPET imaging.
Ga-NOTA-SNA006a, a novel Nanobody tracer targeting human CD8 antigen, was developed with high radiochemical purity and high affinity. Compared with other candidates, the long retention time, low background, excellent TBRs of Ga-NOTA-SNA006a make it precisely track the human CD8 T cells in mice models, showing great potential for immunotherapy monitoring and efficacy evaluation.
尽管免疫疗法已经彻底改变了某些类型癌症的治疗策略,但大多数患者未能响应或获得长期获益。肿瘤浸润 CD8 T 淋巴细胞与患者的治疗效果和预后密切相关。因此,非侵入性地阐明系统和肿瘤浸润 CD8 T 淋巴细胞对癌症免疫治疗期间的患者具有非凡的意义。在此,设计了一组 Ga 标记的纳米抗体,通过免疫正电子发射断层扫描(immunoPET)来追踪体内的人 CD8 T 细胞。
在筛选出的纳米抗体中,SNA006a 在体外对人 CD8 蛋白和 CD8 细胞均表现出最高的结合亲和力和特异性,平衡解离常数(K)分别为 6.4×10^-9M 和 4.6×10^-9M。获得了具有高放射化学产率和纯度的 Ga-NOTA-SNA006,无论是在体外还是体内,其稳定性至少保持 1 小时。生物分布和 Micro-PET/CT 成像研究表明,所有示踪剂均特异性地聚集在 CD8 肿瘤中,而在 CD8 肿瘤和正常器官(肾脏除外)中的积聚较低,其中示踪剂被排泄和再吸收。值得注意的是,Ga-NOTA-SNA006a 在 CD8 肿瘤中的摄取快速且持久,在静脉注射后 1.5 小时达到 24.41±1.00% ID/g,导致出色的靶标与背景比(TBR)。更具体地说,肿瘤与肌肉、肿瘤与肝脏以及 CD8 与 CD8 肿瘤的比值分别为 28.10±3.68、5.26±0.86 和 19.58±2.70。此外,在人源化 PBMC-NSG 和 HSC-NPG 小鼠模型中,Ga-NOTA-SNA006a 在 CD8 肿瘤和肝脏、脾脏和肺部等特定组织中积聚,这些组织中人 CD8 抗原过表达或 CD8 T 细胞存在于 immunoPET 成像期间。
新型靶向人 CD8 抗原的纳米抗体示踪剂 Ga-NOTA-SNA006a 具有高放射化学纯度和高亲和力。与其他候选物相比,Ga-NOTA-SNA006a 的长保留时间、低背景和出色的 TBR 使其能够精确地追踪小鼠模型中的人 CD8 T 细胞,为免疫治疗监测和疗效评估提供了巨大潜力。